神经胶质瘤治疗市场基于(关键地区、市场参与者、规模和份额)- 到 2030 年的预测

  • Report Code : TIPRE00029993
  • Category : Pharmaceuticals
  • Status : Published
  • No. of Pages : 182
Buy Now

[研究报告] 2022年,神经胶质瘤治疗市场收入为41.390亿美元,预计到2030年,神经胶质瘤治疗市场规模将达到82.913亿美元。预计2022-2030年复合年增长率为9.1%。
市场洞察和分析师观点:
神经胶质瘤是一种涵盖广泛的大脑和脊髓肿瘤的疾病,涉及大脑功能中的神经胶质细胞,并且根据肿瘤的位置和严重程度可能致命。星形细胞瘤、脑干神经胶质瘤、室管膜瘤、混合神经胶质瘤、少突神经胶质瘤和视神经胶质瘤是各种类型的神经胶质瘤。常见的神经胶质瘤症状包括头痛、恶心、呕吐、精神错乱和大脑功能下降。神经胶质瘤可以通过多种方式治疗,包括神经胶质瘤的放射治疗、化疗、神经胶质瘤靶向治疗和手术。晚期临床管道药物可能可以提供神经胶质瘤的有效治疗方法。
增长动力和机遇:
地区和州政府为患者提供治疗机会的举措
2021 年 12 月,患者访问网络 (PAN)基金会和美国脑肿瘤协会宣布建立新的合作伙伴关系,为胶质母细胞瘤患者提供每年高达 1,600 美元的财务援助。此外,神经胶质瘤治疗市场的领先公司专注于推出新产品和开发现有产品。 2020年12月,CNS Pharmaceuticals, Inc.宣布美国食品药品监督管理局授权使用贝柔比星治疗多形性胶质母细胞瘤患者。此外,美国食品和药物管理局于 2021 年 8 月将 Lantern Pharma Inc. 的 LP-184 指定为孤儿药,用于治疗多形性胶质母细胞瘤和其他恶性胶质瘤。 2020 年 5 月还举办了一场关于多形性胶质母细胞瘤 (GBM) 以及 Lantern Pharma 的 LP-184 治疗 GBM 和其他类型脑癌的潜力的网络研讨会。因此,地区和州政府为向患者提供新疗法而做出的努力加速了神经胶质瘤治疗市场的增长。
新兴经济体医疗保健行业的进步
巴西、俄罗斯、印度、中国和南非 (金砖国家) 是世界上增长最快的经济体之一。这些国家以及其他发展中经济体的医疗保健行业预计将在未来几年迅速扩张。预期增长归因于客户需求的变化、医疗保健服务意识的提高以及人口老龄化的持续增长。随着医疗保健行业的蓬勃发展,全球脑癌诊断市场可能在未来几年显着增长。此外,政府在医疗保健设施上的支出和消费者购买力的增加有助于发展中国家医疗保健行业的增长。
由于正在进行的临床研究、集中医疗机构、高素质、积极性高的员工队伍以及优良的临床试验设施。此外,亚太地区许多国家拥有庞大且多样化的患者库,约 60% 的全球人口居住在该地区。亚太地区遵循美国和欧盟监管机构制定的治疗指南来治疗疾病,这为大量、快速招募患者提供了坚实的前景。因此,亚太地区发展中国家不断增长的医疗保健行业为神经胶质瘤治疗市场参与者扩大业务创造了更好的机会。
战略见解
报告细分和范围:
“全球神经胶质瘤治疗市场”是细分为疾病、治疗类型、等级、最终用户和地理位置。根据疾病,神经胶质瘤治疗市场分为星形细胞瘤、少突星形细胞瘤和少突胶质细胞瘤。根据治疗类型,神经胶质瘤治疗市场分为手术、化疗、放射治疗等。全球神经胶质瘤治疗市场按级别分为低级别和高级别。 2022年,高档细分市场将占据更大的市场份额。按最终用户划分,神经胶质瘤治疗市场分为医院和诊所以及门诊手术中心。从地理上看,神经胶质瘤治疗市场分为北美(美国、加拿大和墨西哥)、欧洲(德国、法国、意大利、英国、俄罗斯和欧洲其他地区)、亚太地区(澳大利亚、中国、日本、印度) 、韩国和亚太地区其他地区)、中东和非洲(南非、沙特阿拉伯、阿联酋以及中东和非洲其他地区)以及南美洲和中美洲(巴西、阿根廷以及中南部和中部其他地区)美国)。
细分分析:
根据疾病,神经胶质瘤治疗市场分为星形细胞瘤、少突星形细胞瘤和少突胶质细胞瘤。 2022 年,星形细胞瘤细分市场占据最大市场份额,预计 2022 年至 2030 年复合年增长率将达到 9.4%。星形细胞瘤,也称为恶性神经胶质瘤,通常发生在大脑的大脑半球。间变性星形细胞瘤是一种罕见的恶性脑肿瘤。星形细胞瘤由星形胶质细胞(星形脑细胞)发展而来。星形胶质细胞和类似的细胞称为神经胶质细胞,它们形成的组织称为神经胶质组织,在大脑或脊髓中发育。源自神经胶质组织的肿瘤包括星形细胞瘤,被称为神经胶质瘤。间变性星形细胞瘤的症状因肿瘤部位和大小而异。间变性星形细胞瘤的治疗方法是最大程度地手术切除,然后进行放射治疗。治疗方案可能包括神经外科手术、放射治疗或化疗的组合。
Avid Bioservices, Inc.;默克·夏普·多姆公司;迈兰 NV、诺华公司;和 F. Hoffmann-La Roche Ltd. 是提供用于神经胶质瘤治疗的产品的著名公司之一。提高公众对这种疾病及其治疗认识的活动激增,加上这种疾病患病率的不断增加,是推动神经胶质瘤治疗市场增长的主要因素之一。此外,在间变性星形细胞瘤市场上运营的公司可能会从不断增长的研发努力和新的、未开发的细分市场中获得增长机会。
根据治疗类型,神经胶质瘤治疗市场分为手术、化疗、放射治疗、和别的。其他治疗包括靶向药物治疗、电场和磁场治疗以及联合治疗。 2022年,手术领域占据神经胶质瘤治疗市场的最大份额。进一步估计 2022 年至 2030 年复合年增长率将达到 9.7%。手术是最优选的技术,因为它可以完全切除肿瘤。计算机断层扫描 (CT) 扫描和磁共振成像 (MRI) 帮助神经外科医生定位并精确切除大脑或脊髓的肿瘤。外科医生通过打开颅骨到达肿瘤部位来进行开颅手术。外科手术可以减少脑内实体瘤组织的数量;去除肿瘤中心的细胞,这些细胞可能对放射和/或化疗有抵抗力;并降低颅内压。通过减灭肿瘤,外科手术可以延长一些患者的生命并提高剩余生活质量。
神经胶质瘤治疗市场,按治疗类型 - 2022 年和 2030 年
全球神经胶质瘤治疗市场,按级别,分为低品位和高品位。 2022年,高档细分市场将占据更大的市场份额。进一步估计 2022 年至 2030 年复合年增长率将达到 9.4%。高级别胶质瘤被分级为 3 或 4,表明它们更具侵袭性,并且更快地生长到大脑或脊髓,这使得它们的诊断和治疗变得困难。高级别神经胶质瘤可能无法治愈。手术、放射和靶向治疗可以减缓肿瘤生长并有助于缓解症状。由于大多数类型的高级别胶质瘤没有治愈方法,因此鼓励许多人参加临床试验。多项研究正在进行中,以更好地了解高级别肿瘤,以开发更有效的治疗方法或疗法。高级别神经胶质瘤是儿童中第二常见的恶性(癌性)脑肿瘤类型。
按最终用户划分,神经胶质瘤治疗市场分为医院和诊所以及门诊手术中心。 2022 年,医院和诊所细分市场占据更大份额,预计 2022 年至 2030 年复合年增长率将达到 9.2%。医院和诊所作为初级保健中心,聘用合格的医疗和保健人员,为患者提供便捷的服务和最好的护理。大多数医院提供的胶质瘤治疗都包含在保险范围内,鼓励患者到医院接受治疗。此外,以尽可能最好的方式提供术后护理,以防止进一步的并发症。由于所有服务均在同一屋檐下提供,因此医院在世界各地基本上都是首选。此外,这些国家拥有多家医院,患者可以选择不同的治疗方案。接触全球趋势、增加可支配收入和无麻烦的报销流程是导致脑癌患者到医院就诊的人数不断增加以及脑癌手术数量激增的常见因素。由于医院拥有先进的医疗设备,因此可以利用医院的基础设施为各种脑癌病例提供高质量的护理。据估计,医院部门在神经胶质瘤治疗市场中占有相当大的份额,因为新兴国家和发达国家的大多数患者更喜欢到医院接受健康相关问题的治疗。此外,发展中国家医院数量的增加、先进诊断平台的采用以及医院的可及性不断提高,将为 2022 年至 2030 年医院领域神经胶质瘤治疗市场的增长提供利润丰厚的机会。
区域分析:< br>从地理上看,神经胶质瘤治疗市场分为北美、欧洲、亚太地区、中东和非洲以及南美洲和中美洲。欧洲的神经胶质瘤治疗市场分为法国、德国、意大利、西班牙、英国和欧洲其他地区。该地区在全球市场中占有第二大份额,这可归因于脑肿瘤病例数量的增加、法国脑肿瘤治疗技术的进步、英国神经系统疾病患病率的增加以及英国医疗保健投资的激增。德国。英国的医疗保健部门拥有发达的先进医疗技术和设备。据英国国家卫生服务中心统计,英国每年有超过11000人被诊断患有脑肿瘤,其中近50%的肿瘤是癌性的。根据 Globocan 2020 数据,英国记录了约 7,697 例新发脑癌和中枢神经系统癌病例。由于发病率迅速上升,一些私人和政府组织正在投资癌症研究。根据英国癌症研究中心 (BCCR0001) 于 2021 年 4 月发布的与脑肿瘤和儿童癌症研究相关的书面证据,英国癌症研究中心自 2018 年以来已承诺拨款 3545 万美元,通过资助脑肿瘤研究和启动卓越中心和辐射研究网络。该中心在2019-2020年投资1520万美元用于脑肿瘤研究,并投资1112万美元用于影响儿童和青少年的癌症研究,成为英国脑肿瘤领域最大的研究资助者之一。
欧洲拥有完善的医疗保健系统,可为各种医疗状况提供世界一流的诊断和治疗服务。此外,基础设施的发展预计将提高医院对技术先进的医疗实践的需求。欧盟国家将其 GDP 的近 10.9% 用于医疗保健系统。因此,医疗保健发展的崛起可能有利于 2022-2030 年欧洲神经胶质瘤治疗市场的增长。该地区人均收入高,医疗基础设施先进,这意味着对各种尖端医疗和诊断的需求。
俄罗斯、波兰、奥地利、瑞士、瑞典、挪威、丹麦、比利时和荷兰是欧洲其他地区的主要国家之一。癌症病例数量的增加导致对神经胶质瘤治疗的需求,以及使用新技术先进医疗设施的医院数量的增加可能会给欧洲其他地区的神经胶质瘤治疗市场带来巨大的增长机会。人口增长、经济繁荣、吸烟者数量的增加(脑癌的危险因素)、对更快诊断的需求激增以及诊断设备的改进是推动其他地区神经胶质瘤治疗市场的关键因素
行业发展和未来机遇:
全球胶质瘤治疗市场主要参与者采取的各种举措如下:
2023 年 7 月,F. Hoffmann-La Roche 开发了 RG-6156,该药物正处于临床开发阶段,目前正处于针对多形性胶质母细胞瘤(GBM)的一期临床研究中。 EGFRvIII x CD3 (RG6156) 是一种 T 细胞双特异性抗体,可与肿瘤细胞上的 EGFRvIII 和 T 细胞上的 CD3 结合。 EGFRvIII 是一种激活 EGFR 突变,导致致瘤性增加,在约 30% 的胶质母细胞瘤 (GBM) 中表达。 2022 年 10 月,Amneal 在美国推出了 ALYMSYS(贝伐珠单抗-maly)的首款生物仿制药。美国的 ALYMSYS(贝伐单抗-maly)是一种血管内皮生长因子抑制剂,适用于治疗成人复发性胶质母细胞瘤以及其他癌症治疗。2021 年 8 月,Azurity Pharmaceuticals 收购了 Arbor Pharmaceuticals。合并后的公司将以 Azurity 名义运营,将拥有一系列产品,满足心血管、中枢神经系统、内分泌、胃肠道和机构市场患者未满足的需求。COVID-19 影响:
在新冠疫情之前的情况下为了有效治疗胶质瘤,我们不断进行研究和开发活动,包括手术切除随后进行放化疗和化疗,以提高患者的生存率。在美国国立卫生研究院的资助下,市场主要参与者专注于各种增长战略;例如,神经胶质瘤治疗方案的纳米技术研发。由于 COVID-19 爆发后治疗重点发生了变化,这些活动被推迟了一段时间。
COVID-19 大流行扰乱了医疗保健系统,导致人们担心其对非 COVID 疾病的后续影响。癌症的诊断和治疗具有时间敏感性,并且可能会受到这些情况的显着影响。每个癌症学科的活动都受到了 COVID-19 大流行的不利影响。此外,儿童恶性脑肿瘤的特点是生长迅速,需要早期诊断和适当的治疗。因此,延迟或修改治疗可能会损害其有效性并降低患者的生存率。由于SARS CoV2感染的恐惧和压力,脑肿瘤儿童决策过程的变化可能会在一定程度上对其最终结果产生负面影响。
竞争格局和主要公司:
部分全球神经胶质瘤治疗市场的知名参与者包括 F. Hoffmann-La Roche Ltd;阿伯制药有限责任公司;默克公司;太阳制药工业有限公司;安进公司;梯瓦制药工业有限公司;辉瑞公司; Amneal 制药有限责任公司; Karyopharm 治疗公司;和布里斯托梅耶斯施贵宝公司。这些公司专注于新产品发布和地域扩张,以满足全球不断增长的消费者需求,并增加其专业产品组合的产品范围。他们在全球范围内拥有广泛的业务,这使他们能够为大量客户提供服务,从而增加他们的市场份额。该报告提供了神经胶质瘤治疗市场前景的趋势分析,强调了技术进步、市场动态和竞争格局分析等各种参数全球领先的市场参与者。
Report Coverage
Report Coverage

Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

Segment Covered
Segment Covered

This text is related
to segments covered.

Regional Scope
Regional Scope

North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

Country Scope
Country Scope

This text is related
to country scope.

Frequently Asked Questions


What is meant by the glioma treatment market?

Glioma is a condition that covers a broad category of brain and spinal cord tumors that concern the glial cells in the brain function and can be fatal depending on the location and severity of the tumor. Astrocytoma, brainstem gliomas, ependymoma, mixed gliomas, oligodendrogliomas, and optic pathway gliomas are the various types of gliomas. Common glioma symptoms include headache, nausea, vomiting, confusion, and a decline in brain function. Glioma can be treated in a variety of ways which include radiation therapy for glioma, chemotherapy, glioma-targeted therapy, and surgery. Effective treatment of glioma may be available from late clinical pipeline drugs.

What are the driving factors for the glioma treatment market across the globe?

Increasing various initiatives undertaken by the regional and state governments to provide patients access to treatment and increase in prevalence of high-grade glioma are the key driving factors behind the market development.

Which disease segment led glioma treatment market?

Based on disease, the glioma treatment market is segmented into astrocytoma, oligoastrocytoma, and oligodendroglioma. In 2022, the astrocytoma segment held the largest share of the market. The same segment is estimated to record at a significant CAGR of during the forecast period.

Who are the key players in the glioma treatment market?

Companies operating in the market are F. Hoffmann-La Roche Ltd; Arbor Pharmaceuticals, LLC; Merck and Co., Inc.; Sun Pharmaceutical Industries Ltd; Amgen Inc.; Teva Pharmaceutical Industries Ltd.; Pfizer Inc.; Amneal Pharmaceuticals, LLC; Karyopharm Therapeutics, Inc.; and Biocon Ltd.

What is the regional market scenario of the glioma treatment market?

Global glioma treatment market is segmented by region into North America, Europe, Asia Pacific, the Middle East & Africa, and South & Central America. North America is likely to continue its dominance in the glioma treatment market during 2022–2028. The US holds the largest share of the market in North America and is expected to continue this trend during the forecast period.

Which treatment type segment held the largest revenue (US$ Mn) in the glioma treatment market?

The global glioma treatment market, by treatment type, is segmented into surgery, chemotherapy, radiation therapy, and others. The other treatments include targeted drug therapy, electric and magnetic fields, and combination therapies. In 2022, the surgery segment held the largest share of the glioma treatment market. It is further estimated to register a significant CAGR during the forecast period.

The List of Companies - Glioma Treatment Market

  1. F. Hoffmann-La Roche Ltd
  2. Arbor Pharmaceuticals, LLC
  3. Merck and Co., Inc.
  4. Sun Pharmaceutical Industries Ltd
  5. Amgen Inc.
  6. Teva Pharmaceutical Industries Ltd.
  7. Pfizer Inc.
  8. Amneal Pharmaceuticals, LLC
  9. Karyopharm Therapeutics, Inc.
  10. Bristol Mayers Squibb Company

The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.

  1. Data Collection and Secondary Research:

As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.

Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.

  1. Primary Research:

The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.

For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.

A typical research interview fulfils the following functions:

  • Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
  • Validates and strengthens in-house secondary research findings
  • Develops the analysis team’s expertise and market understanding

Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:

  • Industry participants: VPs, business development managers, market intelligence managers and national sales managers
  • Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.

Below is the breakup of our primary respondents by company, designation, and region:

Research Methodology

Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.

  1. Data Analysis:

Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.

  • Macro-Economic Factor Analysis:

We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.

  • Country Level Data:

Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.

  • Company Profile:

The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.

  • Developing Base Number:

Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.

  1. Data Triangulation and Final Review:

The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.

We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.

We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.

Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Related Reports